Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January
View HTML
Toggle Summary Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
WHIPPANY, N.J. & SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2020-- Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation January 2021